Alpha 2.0
Login Register
» Articles » PMID: 33014710

Cavitary Pulmonary Tuberculosis with COVID-19 Coinfection

Overview
Journal IDCases
Specialty Infectious Diseases
Date 2020 Oct 5
PMID 33014710
Citations 21
Authors
Zohaib Yousaf
Adeel A Khan
Haseeb A Chaudhary
Kamran Mushtaq
Jabeed Parengal
Mohamad Aboukamar
Muhammad Umair Khan
Mouhand F H Mohamed
Affiliations
Soon will be listed here.
Abstract

The COVID-19 pandemic has strained the healthcare system worldwide, leading to an approach favoring judicious resource allocation. A focus on resource preservation can result in anchoring bias and missed concurrent diagnosis. Coinfection (TB) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has implications beyond morbidity at the individual level and can lead to unintended TB exposure to others. We present six cases of COVID-19 with newly diagnosed cavitating pulmonary tuberculosis to highlight the significance of this phenomenon and favorable outcomes if recognized early.

Citing Articles

Drug-Resistant TB, HIV and COVID-19 Co-Infection: Case Reviews from Kwa-Zulu Natal, South Africa.

Hassan-Moosa R, Motsomi K, Narasimmulu R, Sivro A, Naidu K, Kharsany A Infect Drug Resist. 2023; 16:7663-7670.

PMID: 38126006 PMC: 10731725. DOI: 10.2147/IDR.S433695.

COVID-19 and pulmonary Tubercuiosis coinfection: three case reports from Iran.

Nasiri M, Shakibaei S Indian J Tuberc. 2023; 70(4):497-500.

PMID: 37968057 PMC: 10066582. DOI: 10.1016/j.ijtb.2023.03.021.

The Impact of the COVID-19 Pandemic on Antimicrobial Resistance and Management of Bloodstream Infections.

Petrakis V, Panopoulou M, Rafailidis P, Lemonakis N, Lazaridis G, Terzi I Pathogens. 2023; 12(6).

PMID: 37375470 PMC: 10302285. DOI: 10.3390/pathogens12060780.

COVID-19 and tuberculosis coinfection: An overview of case reports/case series and meta-analysis of prevalence studies.

Daneshvar P, Hajikhani B, Sameni F, Noorisepehr N, Zare F, Bostanshirin N Heliyon. 2023; 9(2):e13637.

PMID: 36789387 PMC: 9911156. DOI: 10.1016/j.heliyon.2023.e13637.

Clinical Outcomes of Individuals with COVID-19 and Tuberculosis during the Pre-Vaccination Period of the Pandemic: A Systematic Review.

Jhaveri T, Fung C, LaHood A, Lindeborg A, Zeng C, Rahman R J Clin Med. 2022; 11(19).

PMID: 36233523 PMC: 9570663. DOI: 10.3390/jcm11195656.

References
1.
Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C . Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020; 36(7):e3319. PMC: 7228407. DOI: 10.1002/dmrr.3319. View
2.
Giri A, Rana D . Charting the challenges behind the testing of COVID-19 in developing countries: Nepal as a case study. Biosaf Health. 2024; 2(2):53-56. PMC: 7219426. DOI: 10.1016/j.bsheal.2020.05.002. View
3.
Al-Rifai R, Pearson F, Critchley J, Abu-Raddad L . Association between diabetes mellitus and active tuberculosis: A systematic review and meta-analysis. PLoS One. 2017; 12(11):e0187967. PMC: 5697825. DOI: 10.1371/journal.pone.0187967. View
4.
Walaza S, Tempia S, Dawood H, Variava E, Moyes J, Cohen A . Influenza virus infection is associated with increased risk of death amongst patients hospitalized with confirmed pulmonary tuberculosis in South Africa, 2010-2011. BMC Infect Dis. 2015; 15:26. PMC: 4316613. DOI: 10.1186/s12879-015-0746-x. View
5.
Donovan M, Schultz T, Duke T, Blumenthal A . Type I Interferons in the Pathogenesis of Tuberculosis: Molecular Drivers and Immunological Consequences. Front Immunol. 2017; 8:1633. PMC: 5711827. DOI: 10.3389/fimmu.2017.01633. View